Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.

You may also be interested in...



Erbitux Open-label Results For NSCLC Hardly Stellar

Still, the BMS-099 study supports results of the much larger and better-powered FLEX study, ImClone says.

Erbitux Open-label Results For NSCLC Hardly Stellar

Still, the BMS-099 study supports results of the much larger and better-powered FLEX study, ImClone says.

FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC

Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel